Acumen Pharmaceuticals (ABOS) Set to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) will be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.36) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). During the same period in the prior year, the company earned ($0.28) EPS. On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Up 7.7 %

Shares of Acumen Pharmaceuticals stock traded up $0.23 during midday trading on Wednesday, reaching $3.23. 392,763 shares of the company's stock traded hands, compared to its average volume of 329,592. The company has a market cap of $194.06 million, a price-to-earnings ratio of -2.83 and a beta of 0.04. Acumen Pharmaceuticals has a 52 week low of $1.81 and a 52 week high of $5.09. The company's 50 day simple moving average is $2.56 and its 200 day simple moving average is $2.80. The company has a debt-to-equity ratio of 0.12, a quick ratio of 17.37 and a current ratio of 17.37.

Analysts Set New Price Targets

A number of analysts have weighed in on ABOS shares. Citigroup raised Acumen Pharmaceuticals to a "strong-buy" rating in a research report on Friday, July 26th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Thursday, October 3rd. Finally, UBS Group lowered their price target on Acumen Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating on the stock in a report on Thursday, August 15th.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.